Financing ·
On June 10, 2026, Xeris Biopharma Holdings, Inc. entered into exchange agreements with holders of its 8.00%…
XERSXeris Biopharma Holdings, Inc.
On June 10, 2026, Xeris Biopharma Holdings, Inc. entered into exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. Noteholders agreed to exchange approximately $23 million in aggregate principal—representing about 69% of the outstanding 2028 Notes—for a combination of cash and common stock. The cash portion equals the principal amount of the exchanged notes, funded by on-hand liquidity, while the share portion will be based on the 21-day volume-weighted average price starting June 11, 2026. The transaction is expected to close around July 15, 2026, leaving $10.5 million of the 2028 Notes outstanding. The company is a biopharmaceutical company that develops and commercializes injectable therapies.